Administration of beta blockers for over a year is found to be effective in reducing the risk of death

Although beta blockers reduce the burden of ischemia in the heart and have antiarrhythmic effects, they can cause side effects, including bradycardia, hypotension, and claudication. Therefore, it is critical to set the appropriate treatment period. Currently, international guidelines recommend starting beta-blocker treatment at the beginning of all acute myocardial infarctions. However, how long the beta-blocker therapy should be used in patients without heart failure is not known.

 

The research team analyzed data obtained from monitoring 28,970 myocardial infarction patients over 18 years of age with no heart failure for 3.5 years.

 

The results showed that the number of deaths confirmed during the monitoring reached 1,694, and 25.7 deaths occurred per 1,000 person-years when the beta blocker was used for less than one year, while 13.1 deaths per 1,000 person-years occurred when the beta blocker was used for more than one year. Even when the basic characteristics, treatment history, and disease history of the two groups were strictly controlled, the risk of death significantly decreased when the beta blocker was used for more than one year.

 

The risk of hospitalization due to relapse of acute myocardial infarction and heart failure was significantly lower in the group that used the beta blocker for one year or more. In addition, when the beta blocker was used for more than 2 or 3 years, the long-term risk of death and related disease development was lowered.

 

The results were published in the European Heart Journal (IF=24.889) with the highest impact in the cardiovascular field.